Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta-analysis

被引:0
|
作者
Yu, Jiahui [1 ]
Yan, Duan [1 ]
Wei, Song [1 ]
Yang, Linfeng [1 ]
Yi, Pengsheng [1 ]
机构
[1] North Sichuan Med Coll, Affiliated Hosp, Dept Hepatobiliary Pancreas 2, 1 Maoyuan South Rd, Nanchong 637000, Sichuan, Peoples R China
关键词
transcatheter arterial chemoembolization; tyrosine kinase inhibitors; camrelizumab; hepatocellular carcinoma; meta-analysis; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; TRANSARTERIAL CHEMOEMBOLIZATION; DOUBLE-BLIND; MULTICENTER; APATINIB; THERAPY; ANTIBODIES; LENVATINIB; TRIALS;
D O I
10.3892/ol.2024.14534
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transcatheter arterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) and camrelizumab (collectively: T-T-C) is a novel treatment strategy for unresectable hepatocellular carcinoma (HCC). The present systematic review and meta-analysis aimed to evaluate the efficacy and safety of T-T-C compared with TACE combined with TKIs only (T-T) in the treatment of patients with unresectable HCC. A systematic literature search was conducted on T-T and T-T-C using PubMed, Embase and the Cochrane Library. Data regarding the clinical outcome, including overall survival (OS), progression-free survival (PFS), tumor response and adverse events (AEs), were independently extracted and analyzed by two researchers using standardized protocols. In total, 7 cohort studies, including 1,798 patients (T-T-C, 838; T-T, 960), were included in the meta-analysis. The results of the present study demonstrated that the T-T-C group had significantly prolonged OS [hazard ratio (HR), 0.38; 95% confidence interval (CI), 0.29-0.50; I2=61.5%; P=0.016)] and PFS (HR, 0.37; 95% CI, 0.30-0.46; I2=44.5%; P=0.109), and showed significantly higher objective response rates [risk ratio (RR), 0.82; 95% CI, 0.69-0.96; I2=25.1%; P=0.237)] and slightly higher disease control rates without a significant difference (RR, 0.96; 95% CI, 0.89-1.03; I2=0.0%; P=0.969). In addition, grade 3/4 AEs were more common in the T-T group, including hypertension (RR, 1.15; 95% CI, 0.85-1.56), vomiting or nausea (RR, 0.88; 95% CI, 0.44-1.76) and pain (RR, 0.74; 95% CI, 0.45-1.21); however, these results were not statistically significant. In conclusion, compared with T-T combination therapy, T-T-C demonstrated a notable advantage in terms of OS, PFS, ORR and DCR in patients with unresectable HCC. For manageable AEs, although the results were not statistically significant, the incidence of AEs in the T-T group was higher than that in the T-T-C group in terms of event probability.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
    Gupta, Nandini
    Verma, Neelkant
    Patel, Bhoomika
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (04) : 1485 - 1497
  • [42] Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis
    Xian, Feng
    Wu, Cailiang
    Zhang, Guojun
    Xu, Guohui
    MEDICINE, 2022, 101 (44) : E31479
  • [43] Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis
    Chen, Yue
    Jia, Luyao
    Li, Yu
    Cui, Wenhao
    Wang, Jukun
    Zhang, Chao
    Bian, Chunjing
    Luo, Tao
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [44] Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis
    Lei, Qing
    Yan, Xin
    Zou, Huimin
    Jiang, Yixuan
    Lai, Yunfeng
    Ung, Carolina Oi Lam
    Hu, Hao
    DISCOVER ONCOLOGY, 2022, 13 (01)
  • [45] Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis
    Qing Lei
    Xin Yan
    Huimin Zou
    Yixuan Jiang
    Yunfeng Lai
    Carolina Oi Lam Ung
    Hao Hu
    Discover Oncology, 13
  • [46] Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
    Maano, O. P.
    Malbas, J. M. V.
    Dy, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S614 - S614
  • [47] Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re-analysis of a meta-analysis
    Zhou, Shouhao
    Shen, Chan
    JGH OPEN, 2023, 7 (02): : 163 - 164
  • [48] Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Payo-Serafin, Tania
    Mendez-Blanco, Carolina
    Fernandez-Palanca, Paula
    Martinez-Geijo, Jennifer
    Reviejo, Maria
    Ortiz-de-Urbina, Juan Jose
    Gonzalez-Gallego, Javier
    Marin, Jose J. G.
    Mauriz, Jose L.
    San-Miguel, Beatriz
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, : 328 - 345
  • [49] Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2024, 13 (03) : 227 - 234
  • [50] Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study
    Chen, Yu-Xing
    Zhang, Jin-Xing
    Zhou, Chun-Gao
    Liu, Jin
    Liu, Sheng
    Shi, Hai-Bin
    Zu, Qing-Quan
    Cheng, Yuan
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (02) : 924 - 931